AI-optimized drugs vs standard treatment for TB
Part of Infections, Lungs & breathing clinical trials.
This trial tests whether a combination of pyrazinamide and hydroxychloroquine, guided by artificial intelligence, works better than the standard 4-drug regimen for drug-sensitive pulmonary tuberculosis. If effective, this could shorten treatment or reduce side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have active tuberculosis that is confirmed to be sensitive to standard drugs.
- You must be between 18 and 65 years old.
- You must have not been treated for TB before, or only for less than 1 month.
- You must be willing to attend study visits and follow procedures.
- If you have HIV, your CD4 count must be 200 or higher and you must be on stable HIV treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new combinations of TB medicines for people with active lung TB that is sensitive to standard drugs. It aims to find safer, shorter treatments that work just as well or better than current options.
This trial tests a combination of drugs for people with active tuberculosis who have not been treated before. It aims to find a better way to treat TB, even if the bacteria are resistant to some drugs.
This Phase 2 study tests treatment for people with newly diagnosed, drug-susceptible pulmonary (lung) tuberculosis (TB). It aims to see whether the study treatment works well and is safe for curing TB.
This trial tests a three-drug combination (bedaquiline, delamanid, and linezolid) to see if it's safe and works well for people with multi-drug resistant or rifampicin-resistant tuberculosis. It may offer a new treatment option if standard drugs aren't working.
This study tests different ways to treat active lung TB that is not resistant to rifampicin. It aims to find the best treatment duration and combination to cure TB and prevent it from coming back.
This study is testing new combinations of drugs to treat tuberculosis (TB) in the lungs. It aims to find a more effective and shorter treatment, and you may benefit from receiving these new drugs while helping advance TB research.
Hear when a new Pulmonary Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.